



On reflection, no other treatment looks so convenient

Many women with genital warts would welcome the convenience and dignity of treating themselves at home.

New Warticon Fem makes self-treatment practical by the simple inclusion of a mirror in every pack.

Proven to be effective¹ and well tolerated² when used in this way,

Warticon Fem is now a clear first choice treatment.

ABBREVIATED PRESCRIBING INFORMATION Warticon, Warticon Fem: Podophyllotoxin 0.5% w/v. **Presentation:** An acidic ethanolic solution of 0.5% w/v podophyllotoxin. **Uses:** For the topical treatment of condyloma acuminata affecting the penis or the female external genitalia. **Dosage and Administration:** The affected area should be thoroughly washed with soap and water, and dried prior to application. Using the applicator provided, the warts should be painted twice daily for 3 days. The treated area should be allowed to dry. If residual warts persist, this 3-day treatment may be repeated, at weekly intervals, if necessary, for a total of 4 weeks of treatment. The majority of patients will not require in excess of 30 loops for each application, however a maximum of 50 loops per application (equivalent to 250µl of Warticon Solution) may be applied. Where lesions are greater in area than 4cm², it is recommended that treatment takes place under the direct supervision of medical staff. **Contra-Indications, Warnings, etc:** Open wounds following surgical procedures should not be treated with podophyllotoxin. Hypersensitivity to podophyllotoxin is a contra-indication. Avoid contact with the eyes. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. **Side effects:** Local irritation may occur on the second or third day of application associated with the start of wart necrosis. In the majority of cases the reactions are mild. Tenderness, smarting, erythema, superficial epithelial ulceration and balanoposthitis have been reported. Local irritation decreases after treatment. **Use in Pregnancy:** Do not use during pregnancy or lactation. **Overdosage:** There have been no reported overdoses with Warticon Solution. No specific antidote is known. Following accidental spillage, wash the skin well with soap and water. In the event of accidental ingestion give emetic or stomach washout. Treatment should be symptomatic and in severe oral overdose ensure the airway is clear and give fluids, check and correct electrolyte balance, monitor blood gases and liver function. Blood count should be monitored for at least five days. **Pharmaceutical Precautions:** Product should be stored at room temperature. **Legal Category:** POM. **Package Quantities:** Each bottle contains 3ml of Warticon Solution. Plastic applicators are also enclosed in each pack. Each loop will carry a volume of approximately 5µl Warticon Solution. Warticon Fem also contains a mirror to facilitate accurate application. **Basic NHS Cost:** Warticon 3ml £16.00, Warticon Fem 3ml £16.00. **Product Licence Number:** PL3863/0007 **Date of Preparation:** June 1993.

NEW
Warticon
fem
Podophyllotoxin 0.5%w/v

Clearly simple enough for
self-application in female genital warts




Further information is available from: Perstorp Pharma Ltd, Intec 2, Wade Road, Basingstoke, Hants RG24 8NE. Tel: 0256 477868.

REFERENCES 1. Baker D. A. et al. *Obstet Gynaecol* 1990; 76: 656-9. 2. Kinghorn G. R. et al. 1993; In press.

® and Warticon are registered trademarks.

What's wrong with medical education?



Many medical graduates are unprepared for the realities of being a doctor. After five years of absorbing factual information, their creative thinking and problem solving skills are poor. Something is wrong with the way students are being taught.

In *Medical Education* Stella Lowry has put together the current views from the

profession, the GMC's recent review, and a national consensus inquiry by the King's fund. She examines issues such as:

- Selecting and assessing students
- Changing curricula
- Improving the quality of teaching
- Reorganising the preregistration year

The arguments and proposals for improvement are explained clearly, enabling all those involved in teaching medicine – virtually all doctors – to contribute to the debates. The book also provides a valuable insight, for teachers and students alike, into the way forward for medical education.

ISBN 0 7279 0789 1 112 pages 1993 UK £6.95, Overseas £8.00 (BMA Members £6.45, £7.50)

BMJ
PUBLISHING GROUP

ORDER FORM

Available from: **British Medical Journal**, P.O. Box 295, London WC1H 9TE, medical booksellers or the **BMJ bookshop** in BMA House

Please send me _____ copy/ies of **MEDICAL EDUCATION**

Membership No. _____

Name _____
(Print Clearly)

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Address _____

Card No. _____ **Exp** _____

Signature _____

_____ **Postcode** _____

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE

Your resource...

Sexually Transmitted Diseases is your resource for the most current, comprehensive information available on all aspects of sexually transmitted disease. Its unique, multidisciplinary perspective provides insight into the latest advances in the field.

■ **Diagnosis and Treatment**


■ **Etiology ■ Pathology**

■ **Epidemiology ■ Microbiology**

■ **Public Health and Behavior**


Published bi-monthly, *Sexually Transmitted Diseases* brings you original articles on newly identified syndromes, new investigations into the mechanism of disease, descriptions of clinical experiences and reports on therapeutic trials. Features include notes from the CDC, NIH and ASHA, case reports and AVDA news.

Subscribe to the resource you can rely on for the latest, most authoritative information on STDs!



No-Risk Guarantee!

If you're not completely satisfied, you may cancel your subscription at any time and receive a refund for all unmailed issues.



☎ Call us today TOLL FREE
1-800-777-2295 (U.S. except AK)
or FAX your order 301-824-7390.

Published bi-monthly

Annual subscription rates:

Individual \$118.00 (U.S.) - \$130.00 (Other countries)
Institution \$165.00 (U.S.) - \$195.00 (Other countries)

Published by

J. B. Lippincott

A **Wolters Kluwer** Company




Journals Division
J. B. Lippincott
227 East Washington Square
Philadelphia, PA 19106-3780
USA

for the latest information on *Sexually Transmitted Diseases*

Journal of the American Venereal Disease Association
Julius Schachter, PhD, Editor

BASIC MOLECULAR AND CELL BIOLOGY



Second Edition 1993 UK £8.95; Overseas £11.00 (BMA Members £8.45; £10.50)

The study of disease at the molecular and cellular level is revolutionising medicine. Already spectacular progress has been made in identifying the genes involved in some diseases and in understanding cancer pathogenesis, opening up exciting new possibilities for treatment. In *Basic Molecular and Cell Biology* leaders in the field explain the techniques of molecular and cell biology, which are being applied in specialties as far apart as cardiology and diabetes, and describe their implications for medicine. It will enable doctors, students, and researchers to gain a basic understanding of the subject and some insight into the way in which the medical sciences will be moving over the next few years.

This second edition has been extensively updated and expanded, with four new chapters added.

CONTENTS INCLUDE:

- **Molecular and cell biology in clinical medicine: introduction**
David Weatherall
- **The polymerase chain reaction: a tool for molecular medicine**
A F Markham
- **Gene regulation**
David S Latchman
- **Genes and cancer**
Richard G Vile, Myra O McClure, Jonathan N Weber
- **An introduction to cells**
Lewis Wolpert
- **The cell nucleus**
R A Laskey
- **Sorting signals and cellular membranes**
Graham Warren

BMJ
PUBLISHING GROUP

ORDER FORM

Available from: **British Medical Journal, P.O. Box 295, London WC1H 9TE, medical booksellers or the BMJ bookshop in BMA House**

Please send me _____ copy/ies of **Basic Molecular and Cell Biology** **Membership No.** _____

Name _____
(Print Clearly)

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Address _____

Card No. _____ **Exp** _____

Signature _____

_____ **Postcode** _____

☐ Please send me a BMJ PUBLISHING GROUP CATALOGUE



Journal of Medical Screening

Editor: Nicholas Wald

Wolfson Institute of Preventive Medicine

Associate Editors:

J Chamberlain (UK), N E Day (UK), J E Haddow (US), M Law (UK)

Journal of Medical Screening is a new quarterly journal to be launched in January 1994 by the BMJ Publishing Group to cover all aspects of medical screening and advance the science of the discipline. The journal aims to bring together specialist groups conducting screening research and establish a liaison with health authorities and policy developers. The philosophy of the journal is that screening should be about the prevention of disability and disease, not simply the early detection of disease as an end in itself.

The Journal Aims to Cover:

Principles and theory of medical screening

Research into screening methodology

Development of new screening tests and their quantitative evaluation

All aspects of public health as they relate to screening, including epidemiology, randomised trials, quantitative observational studies, demonstration projects and economic evaluations

Ethical and psychological issues

Management issues

Policy and strategy

SUBMISSION

Papers should be submitted to: Professor Nicholas Wald
Wolfson Institute of Preventive Medicine Medical College of St. Bartholomew's Hospital
Charterhouse Square, London EC1M 6BQ, United Kingdom
Tel: 44 71 982 6269 Fax: 44 71 982 6272

Instructions to Authors may be obtained by returning the form below

Order Form

JOURNAL OF MEDICAL SCREENING

PUBLICATION: Quarterly ISSN: 0969-1413

Subscription Rate:

Worldwide: £85.00; Personal Rate*: £52.00

USA Only: \$136.00; Personal Rate*: \$83.00

Please tick

☐ Please enter my subscription; start date _____

☐ Please send me a sample copy

☐ Please send me *Instructions to Authors*

☐ I enclose a cheque for _____
(Payable to British Medical Journal)

☐ I wish to pay by credit card.

American Express/Visa(Barclaycard)/Mastercard
(Delete as appropriate)

* Personal rates are available only on orders placed directly with the publisher and paid for out of personal funds.

Return orders to: Rachel Armitage, BMJ Publishing Group, Journals Marketing Department, PO Box 299, London, WC1H 9TD, UK
or BMJ Publishing Group, Box No. 560B, Kennebunkport, Maine 04046 USA (Direct Orders Only)

Card No.

Expiry Date

Signature

Name (Capitals)

Specialty/Position

Address

Date

The BMA, the *BMJ*, the King's Fund, the College of Health, and *Quality in Health Care* invite you to:

QUALITY '93

RAISING QUALITY IN THE NHS: WHAT PROGRESS?

**KING'S
FUND
CENTRE**

11 November 1993, The Brewery, London EC1

Following the success of the conference on Raising Quality in the NHS held in March 1992, the BMA, the *BMJ*, the King's Fund, the College of Health, and *Quality in Health Care* are organising a follow up conference. The meeting will review progress with raising quality in the NHS and will also look at what's new in raising quality. A particular focus will be on patients involvement.

The meeting is open to doctors, nurses, all health professionals, managers, politicians, researchers, policy makers, and members of the public. Some bursaries will be available to patients unable to afford the full fee.



SESSION A PUTTING PATIENTS AT THE HEART OF RAISING QUALITY

CHAIR: Baroness Jay, Vice Chairman, Parkside Health Authority

What would we do to put patients at the heart of raising quality in the NHS *Marks & Spencer*

Patient defined outcomes *Dr Allyson Ross Davies, New England Medical Center, Boston*

Involving patients in clinical audit *Ms Marianne Rigge, Director, College of Health*

SESSION B NATIONAL INITIATIVES: WHAT PROGRESS?

CHAIR: Dr Robert Maxwell, Secretary & Chief Executive, The King's Fund

Management Executive *Dr Kenneth Calman, Chief Medical Officer, Department of Health*

Clinical Standards Advisory Group *Sir Gordon Higginson, Chairman, CSAG*

Audit commission *Mr Andrew Foster, Controller, The Audit Commission*

SESSION C QUALITY IN PRACTICE: ACHIEVEMENTS SO FAR

CHAIR: Dr Jim Birley, President, BMA

Developments in TQM in the United States *Dr Kent Richards, Intermountain Health Care, Salt Lake City*

Achievements with TQM in the NHS *Professor Alison Kitson, Royal College of Nursing, Oxford*

Achievements of audit in the NHS *Professor Martin Buxton, Health Economics Research Group, Univ. of West London*

How long it takes to see benefits from TQM *Mr Tony Henry, Principal, East Birmingham College*

SESSION D LOOKING FORWARDS

CHAIR: Dr Richard Smith, Editor, *BMJ*

Building quality into contracting and purchasing *Professor Liam Donaldson, Regional General Manager & Director of Public Health, Northern Regional Health Authority*

The links between effectiveness and quality *Mr Trevor Sheldon, Centre for Health Economics, Univ. of York*

Spreading the word - bulletins, journals, databases, networks *Dr Fiona Moss, Editor, "Quality in Health Care"*

BMJ

**College of
Health**

QHC

**Quality in
Health Care**

The conference fee is £110.00 inclusive of VAT, lunch and refreshments, and the Journal's supplement (to be published after the meeting). The closing date for applications is 1st November 1993. An application for PGEA accreditation has been made. *The BMA is grateful to Glaxo Laboratories UK for their support of this event.*

Booking Form

Please complete in block capitals. One form per registrant please

Name and title _____

Name for badge _____

Address _____

Postcode _____ Telephone _____

Profession/occupation/appointment _____

☐ Please send me information about Quality in Health Care

I enclose a cheque/postal order* for £110.00 made payable to the BMA (please do not send cash) *please delete as appropriate

Please debit my Access/Visa* credit card account with £110.00

Access/Visa* account no.

Expiry date

Signature _____ Date _____


essential if paying by credit card

Cardholder's address if different from above _____

VAT No 232 1432 14

Please send this form with your remittance to: Ms Pru Walters, Conference Unit Manager, BMA, BMA House, Tavistock Square, London WC1H 9JP

Abbreviated prescribing information for DIFLUCAN* (fluconazole) *Presentation:* Capsules containing 50mg, 150mg or 200mg fluconazole; intravenous infusion containing fluconazole 2mg/ml in 0.9% sodium chloride solution; Powder for Oral Suspension available as two dosage strengths containing either fluconazole 50mg/5ml or 200mg/5ml on reconstitution with 24ml water. *Indications and dosage:* Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-100mg once daily whilst patients are predisposed to such infections. Dermal fungal infections: 50mg once daily for up to 6 weeks (usually 2-4 weeks - see data sheet). Vaginal candidiasis: single 150mg dose. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. *Administration:* DIFLUCAN may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. *Contra-indications:* Hypersensitivity to fluconazole or related azoles, pregnancy and women of childbearing potential unless adequate contraception is employed. *Warnings:* Lactation: Not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. *Drug interactions:* Anticoagulants, cyclosporin, oral sulphonylureas, phenytoin, rifampicin or theophylline. *Side-effects:* Nausea, abdominal discomfort, diarrhoea, flatulence and rarely anaphylaxis. *Legal Category:* POM. *Basic NHS Cost and Package Quantities:* DIFLUCAN capsules in calendar packs containing 7 x 50mg (£16.61, PL 57/0289), 7 x 200mg (£66.42, PL 57/0317) or 1 x 150mg (£7.12, PL 57/0290); Powder for Oral Suspension, 35ml bottle of 50mg/5ml (£16.61, PL 57/0343), 35ml bottle of 200mg/5ml (£66.42, PL 57/0344); Intravenous Infusion: 25ml (50mg) bottle (£7.32, PL 57/0315), 100ml (200mg) bottle (£29.28, PL 57/0315). Hospital prices are available on request. *References:* 1. Data on file, Pfizer Ltd. 2. Brammer, K.W. (1990), *Haematology and Blood Transfusion*, 33, 546-550. 3. Samonis, G. *et al.* (1990), *Reviews of Infectious Diseases*, 12(3), S369-S373. 4. Data on file, Pfizer Ltd. 5. Buxton, M.J. *et al.* (1991), *Journal of Infection*, 23, 17-31. *Trade Mark. Further information on request. **Pfizer Limited**, Sandwich, Kent.



It takes a
good antifungal
routine
to break the
vicious cycle
of Candida.

DIFLUCAN* is a highly effective antifungal agent with activity against a wide range of common invasive fungal infections.¹ It should be considered as a first-line treatment in suspected or proven candidal or cryptococcal infections. DIFLUCAN also provides effective prophylactic therapy in neutropenic patients and in patients with solid tumours.^{2,3}

DIFLUCAN has a good safety profile and is well tolerated in both its oral and intravenous forms.⁴ Since DIFLUCAN is generally better tolerated than I.V. amphotericin B, patients require less hospital care and can be treated on an outpatient basis thus facilitating a substantial reduction in costs.⁵

Diflucan* ORAL/I.V. Counters invasive fungal infection.
fluconazole *Trade Mark